Medtronic Claims Clinical, Cost Advantages For Just-Launched Viva CRT-D
This article was originally published in The Gray Sheet
Viva is the first of Medtronic’s U.S. CRT-Ds to incorporate the proprietary AdaptivCRT algorithm designed to more readily adapt to a patient’s condition and optimize therapy. The firm also launched its Evera ICD last week.
You may also be interested in...
The first of a planned 3,000 patients have been enrolled in the AdaptResonse trial of Medtronic’s AdaptivCRT cardiac resynchronization algorithm. Previous studies have shown the algorithm reduces hospitalizations, and Medtronic hopes AdaptResponse will show it reduces mortality and medical interventions.
Medtronic announced the European launch its Evera MRI SureScan ICD system, the only implantable defibrillator approved to be compatible with full-body magnetic resonance imaging.
Complete results of the Adaptive CRT study released at the Heart Failure Society of America conference confirm that Medtronic’s AdaptivCRT cardiac resynchronization therapy reduces heart failure hospitalizations compared to regular echo-guided biventricular pacing.